Hexarelin

Hexarelin is a synthetic growth hormone secretagogue that was studied as a relatively potent stimulator of GH release. It is often mentioned alongside GHRP-2 and GHRP-6 but with a distinct pharmacologic profile.

Today, hexarelin is primarily of historical and experimental interest rather than a mainstream therapeutic agent. As with other early secretagogues, regulatory status and product oversight differ markedly between regions and suppliers.

Hexarelin binds to growth hormone secretagogue receptors, promoting GH release in a pulsatile manner. Compared with some peers, it has been described as relatively strong in its GH-stimulating effects.

Like other agents in this class, hexarelin’s actions extend beyond GH alone, potentially influencing appetite, cardiovascular parameters, and other hormonal pathways. The clinical relevance of these broader effects remains an area of discussion rather than settled consensus.

Hexarelin has featured in research exploring GH physiology and in small studies or reports related to metabolic or cardiovascular questions. It is generally not positioned as a standard, labeled treatment for GH deficiency or related conditions in contemporary care.

In informal contexts, hexarelin is sometimes discussed in relation to body composition or performance, but such use typically lies outside regulated indications. Clinical decisions should focus on better-characterized options and adhere to local legal and ethical standards.

Hexarelin is written into the WADA Prohibited List by name, under S2.2.4, "Growth hormone releasing factors." The relevant bullet reads: "GH-releasing peptides (GHRPs) [e.g. alexamorelin, examorelin (hexarelin), GHRP-1, GHRP-2 (pralmorelin), GHRP-3, GHRP-4, GHRP-5 and GHRP-6]." Every substance in class S2 is a non-Specified Substance, which sets the default sanction for a first violation at four years.

A naming trap worth knowing. WADA lists the compound under its INN, examorelin, with "hexarelin" as the parenthetical synonym. An athlete who searches a list or a checker for the trade-adjacent name may not find it if the tool indexes only INNs — but the parenthetical is right there in the official text, and "it wasn't on the list under that name" has never been a defence. The same bullet's opening phrase, "including, but not limited to," means novel GHRP-family analogues are captured whether or not anyone has written them down yet.

Detection. Hexarelin is not a testing blind spot; it was one of the five GH-releasing peptides in the controlled human administration study that established the routine urinary screening targets for this class. Semenistaya and colleagues reported that "Hexarelin and Ipamorelin metabolized intensively and were excreted as a set of parent compounds with metabolites," and that "Hexarelin (1-3) free acid and Ipamorelin (1-4) free acid were detected in urine samples after complete withdrawal of parent substances" (Semenistaya et al., Drug Test Anal 2015). That last point is the operationally important one: the truncated free-acid metabolite outlasts hexarelin itself, so clearance of the parent peptide does not mean clearance of the marker a laboratory actually screens for. The same authors noted that the detection window "depends on individual metabolism, drug preparation form and the way of administration," so no single number can be relied on as a safe interval.

Because hexarelin has no approved therapeutic indication in mainstream practice, there is effectively no clinical route to a therapeutic use exemption for it — a TUE requires a documented medical need that no permitted alternative can meet.

Reported effects have included flushing, injection-site reactions, changes in appetite, and nonspecific symptoms such as headache or fatigue. Some literature has raised questions about potential cardiovascular effects or changes in certain laboratory markers.

As with other GH-axis agents, there is concern about long-term impacts on glucose metabolism, fluid balance, and tissue growth, particularly in people with pre-existing risk factors. These issues are best evaluated in a clinician-supervised context using up-to-date evidence.

Hexarelin is considered one of the most potent GH secretagogues but is prone to causing receptor desensitization with long-term use.

This information summarizes commonly discussed research practices.

Hexarelin is typically supplied as a lyophilized powder for reconstitution. It is a synthetic hexapeptide analog of GHRP-6, developed to be more potent than its parent — and it is the member of this family whose response decline over time has actually been measured, which shapes how it is used more than any formulation question does.

Two features distinguish it from the rest of the class in combination contexts. Its growth hormone effect attenuates measurably with continued dosing — GH area under the curve fell from 19.1 to 10.5 µg/L/h over 16 weeks of twice-daily subcutaneous dosing in 12 healthy elderly volunteers, returning to 19.4 four weeks after stopping (Rahim & Shalet, Growth Horm IGF Res 1998). And it binds CD36 in cardiac tissue, a target unrelated to growth hormone release, giving it an acute cardiovascular action the other secretagogues in common use have not demonstrated (Bodart et al., Circ Res 2002). Neither has been evaluated in a multi-peptide regimen.

Research on hexarelin has explored its effects on GH release, endocrine profiles, and, in some cases, cardiovascular or metabolic endpoints. The resulting literature is relatively specialized and often focused on short-term, mechanistic outcomes.

Given the limited and evolving evidence base, hexarelin is best understood as a tool for understanding GH physiology rather than a broadly established therapy. Clinical or personal decisions should not rely solely on high-level summaries like this.

For deeper dives on this peptide, see:

• Hexarelin benefits and areas of interest
• Hexarelin side effects and safety context
• Hexarelin dosing concepts (educational)
• Hexarelin research and evidence overview

Does hexarelin stop working? Partly, and it has been measured directly. Over 16 weeks of twice-daily subcutaneous dosing in 12 healthy elderly volunteers, growth hormone area under the curve fell from 19.1 µg/L/h at baseline to 13.1 at week 1, 12.3 at week 4 and 10.5 at week 16 (p = 0.0003 overall). Four weeks after stopping, a further dose produced 19.4 — statistically indistinguishable from baseline. The authors concluded the attenuation is "partial and reversible" (Rahim & Shalet, Growth Horm IGF Res 1998).

What is the CD36 connection? Hexarelin binds a target in the heart that is not the ghrelin receptor. Labelling rat cardiac membranes with a photoactivatable hexarelin derivative identified an 84 kDa binding protein whose N-terminal sequence was identical to rat CD36, expressed in cardiomyocytes and microvascular endothelial cells. Hexarelin's dose-dependent increase in coronary perfusion pressure was absent in hearts from CD36-null mice and CD36-deficient rats (Bodart et al., Circ Res 2002).

Does that cardiac effect show up in people? Acutely, yes. In 24 men with coronary artery disease undergoing bypass surgery, hexarelin 2 µg/kg intravenously raised ejection fraction, cardiac index and cardiac output within 10 minutes and for up to 90 — while recombinant growth hormone, GHRH and placebo produced no haemodynamic effect at all (Broglio et al., Eur J Pharmacol 2002). An earlier series found the same rise in healthy adults and in GH-deficient patients — who release essentially no GH in response — but not in patients with severe dilated cardiomyopathy (Broglio et al., Endocrine 2001). These are acute studies under anaesthesia, not evidence of a cardiac therapy.

Is hexarelin "dirtier" than ipamorelin? Less than its reputation suggests, at least subcutaneously. Across 24 hours of sampling every 20 minutes in six healthy young men given 1.5 µg/kg two or three times daily, GH secretory burst mass increased while "no change occurred in the secretion of IGF-I, PRL, ACTH and cortisol" (Maccario et al., Eur J Endocrinol 2002). The hormonal spillover associated with this family appears at large acute intravenous doses.

Is it prohibited in sport? Yes — at all times, under WADA section S2. Hexarelin is extensively metabolised, and both the parent compound and metabolites such as hexarelin (1-3) free acid are targeted in validated anti-doping urine assays (Semenistaya et al., Drug Test Anal 2015).